SEC Form 4 · accession 0001209191-17-051470
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Officer — CEO and Director · Director
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 7:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 31, 2017 | P | 37,736 | $2.65 | A | 367,883 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common StockF1 | $4.64 | Aug 31, 2017 | P | 14,151 | A | Aug 31, 2017 | Dec 31, 2019 | Common Stock | 14,151 | 14,151 | D |
Explanation of responses
- F1Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and a select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock.
- F2Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2017.